COVID-19 与人类乳头瘤病毒：矛盾免疫。
COVID-19 and human papillomavirus: Paradoxical immunity.
机构信息
Department of Dermatology, Evliya Çelebi Training and Research Hospital, Kütahya Health Sciences University, Kütahya, Turkey.
Department of Dermatology, Selçuk University, Konya, Turkey.
出版信息
J Cosmet Dermatol. 2021 Jul;20(7):2001-2003. doi: 10.1111/jocd.14022. Epub 2021 Mar 9.
Abstract
Coronavirus disease 2019 (COVID-19) is a multisystemic disease that can cause progressive lung failure, organ dysfunction, and coagulation disorder associated with high mortality and morbidity. COVID-19 is known to either primarily cause skin symptoms or increase existing skin diseases. Human papillomavirus (HPV) is a DNA virus that can cause benign and malignant neoplasms. Mucocutaneous verruca vulgaris are common benign lesions of HPV. Here, we report a case of verruca vulgaris regressed after COVID-19.
摘要
2019 冠状病毒病（COVID-19）是一种多系统疾病，可导致进行性肺衰竭、器官功能障碍和与高死亡率和发病率相关的凝血障碍。已知 COVID-19 要么主要导致皮肤症状，要么加重现有皮肤病。人乳头瘤病毒（HPV）是一种 DNA 病毒，可引起良性和恶性肿瘤。黏膜寻常疣是 HPV 的常见良性病变。在此，我们报告了一例 COVID-19 后寻常疣消退的病例。
相似文献
1
COVID-19 and human papillomavirus: Paradoxical immunity.
J Cosmet Dermatol. 2021 Jul;20(7):2001-2003. doi: 10.1111/jocd.14022. Epub 2021 Mar 9.
2
Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds.
J Am Acad Dermatol. 2022 Jul;87(1):250-252. doi: 10.1016/j.jaad.2021.08.016. Epub 2021 Aug 18.
3
Topical cidofovir for benign human papillomavirus-associated skin lesions.
Antivir Ther. 2021 Nov;26(6-8):141-146. doi: 10.1177/13596535211059889. Epub 2021 Nov 2.
4
Clearance of longstanding treatment-resistant warts during COVID-19 in a transplant recipient.
Transpl Infect Dis. 2021 Aug;23(4):e13572. doi: 10.1111/tid.13572. Epub 2021 Feb 16.
5
HPV-57 Verruca Vulgaris Mimicking Epidermodysplasia Verruciformis.
Am J Dermatopathol. 2022 Aug 1;44(8):e94-e96. doi: 10.1097/DAD.0000000000002225. Epub 2022 May 30.
6
De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
Oral Oncol. 2020 Jun;105:104768. doi: 10.1016/j.oraloncology.2020.104768. Epub 2020 May 3.
7
Shared Determinants for Human Papillomavirus and COVID-19 Vaccination Intention: An Opportunity for Resource Consolidation.
Am J Health Promot. 2022 Mar;36(3):506-509. doi: 10.1177/08901171211053933. Epub 2021 Nov 5.
8
Human Papillomavirus Vaccination After COVID-19.
JNCI Cancer Spectr. 2021 Mar 2;5(2):pkab011. doi: 10.1093/jncics/pkab011. eCollection 2021 Apr.
9
Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic.
Int J Environ Res Public Health. 2022 Feb 24;19(5):2610. doi: 10.3390/ijerph19052610.
10
The Negative Impact of COVID-19 in HCV, HIV, and HPV Surveillance Programs During the Different Pandemic Waves.
Front Public Health. 2022 Jul 22;10:880435. doi: 10.3389/fpubh.2022.880435. eCollection 2022.
引用本文的文献
1
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
Drugs. 2023 May;83(7):621-632. doi: 10.1007/s40265-023-01867-8. Epub 2023 May 10.
2
COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis.
J Reprod Immunol. 2022 Dec;154:103763. doi: 10.1016/j.jri.2022.103763. Epub 2022 Nov 9.
3
Modern Paradigm Towards Potential Target Identification for Antiviral (SARS-nCoV-2) and Anticancer Lipopeptides: A Pharmacophore-Based Approach.
Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):70-78. doi: 10.18502/ajmb.v14i1.8172.
4
Clearance of recalcitrant verruca plana following COVID-19 vaccination.
JAAD Int. 2022 Sep;8:1-2. doi: 10.1016/j.jdin.2022.02.007. Epub 2022 Mar 16.
本文引用的文献
1
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
Biomed Pharmacother. 2021 May;137:111352. doi: 10.1016/j.biopha.2021.111352. Epub 2021 Feb 2.
2
Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01987-20.
3
SARS-CoV-2 infection and impact on female genital tract: An untested hypothesis.
Med Hypotheses. 2020 Nov;144:110162. doi: 10.1016/j.mehy.2020.110162. Epub 2020 Aug 5.
4
Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D-Dimer.
Dermatol Ther. 2020 Jul;33(4):e13768. doi: 10.1111/dth.13768. Epub 2020 Jul 3.
5
Cutaneous manifestations of COVID-19: A review of the published literature.
Dermatol Ther. 2020 Jul;33(4):e13696. doi: 10.1111/dth.13696. Epub 2020 Jun 24.
6
The trinity of COVID-19: immunity, inflammation and intervention.
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
7
Coronavirus-days ın dermatology.
Dermatol Ther. 2020 Jul;33(4):e13438. doi: 10.1111/dth.13438. Epub 2020 Apr 29.
8
Evolving role of immunotherapy in the treatment of refractory warts.
Indian Dermatol Online J. 2016 Sep-Oct;7(5):364-370. doi: 10.4103/2229-5178.190487.
9
Mechanisms of cell entry by human papillomaviruses: an overview.
Virol J. 2010 Jan 20;7:11. doi: 10.1186/1743-422X-7-11.
Zotero 插件